{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:38:11Z","timestamp":1761586691311,"version":"build-2065373602"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"am","delay-in-days":296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"UNMC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.intimp.2022.108628","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T05:58:32Z","timestamp":1645423112000},"page":"108628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients"],"prefix":"10.1016","volume":"106","author":[{"given":"Kathryn E.","family":"Cole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan P.","family":"Ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt W.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Padussis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Talmadge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"43","key":"10.1016\/j.intimp.2022.108628_b0005","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.108628_b0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/JP9.0000000000000028","article-title":"Adjuvant and neoadjuvant therapy for pancreatic cancer","volume":"2","author":"Maeda","year":"2019","journal-title":"J. Pancreatol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108628_b0015","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","article-title":"Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Tempero","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"4","key":"10.1016\/j.intimp.2022.108628_b0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jamcollsurg.2015.12.017","article-title":"Optimal timing to surgery after neoadjuvant chemoradiotherapy for locally advanced rectal cancer","volume":"222","author":"Sun","year":"2016","journal-title":"J. Am. Coll. Surg."},{"issue":"2","key":"10.1016\/j.intimp.2022.108628_b0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3748\/wjg.v24.i2.257","article-title":"Timing of surgery after neoadjuvant chemotherapy for gastric cancer: impact on outcomes","volume":"24","author":"Liu","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108628_b0030","doi-asserted-by":"crossref","first-page":"e001261","DOI":"10.1136\/jitc-2020-001261","article-title":"Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC","volume":"8","author":"Massa","year":"2020","journal-title":"J. ImmunoTher. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2022.108628_b0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.21037\/tcr.2018.12.30","article-title":"Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy","volume":"8","author":"S\u00e1nchez-Margalet","year":"2019","journal-title":"Transl. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2022.108628_b0040","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/cncr.20130","article-title":"Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma","volume":"100","author":"Fattorossi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2022.108628_b0045","doi-asserted-by":"crossref","first-page":"1804169","DOI":"10.1080\/2162402X.2020.1804169","article-title":"Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response","volume":"9","author":"Kotsafti","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2022.108628_b0050","doi-asserted-by":"crossref","unstructured":"Q. He, G. Li, X. Ji, L. Ma, X. Wang, Y. Li, C. Fan, Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer, Tumor Biol. 39 (2017) 1010428317697571.","DOI":"10.1177\/1010428317697571"},{"key":"10.1016\/j.intimp.2022.108628_b0055","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3389\/fimmu.2018.01739","article-title":"Combining immune checkpoint inhibitors with conventional cancer therapy","volume":"9","author":"Yan","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0060","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.108628_b0065","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0070","doi-asserted-by":"crossref","first-page":"e1581547","DOI":"10.1080\/2162402X.2019.1581547","article-title":"Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis","volume":"8","author":"Chen","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2022.108628_b0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/2159-8290.CD-19-0790","article-title":"Directing traffic: how to effectively drive T cells into tumors","volume":"10","author":"Anandappa","year":"2020","journal-title":"Cancer Disc."},{"issue":"1","key":"10.1016\/j.intimp.2022.108628_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2022.108628_b0085","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.108628_b0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1158\/1541-7786.MCR-20-0917","article-title":"Neoadjuvant chemotherapy induces IL34 signaling and promotes chemoresistance via tumor-associated macrophage polarization in esophageal squamous cell carcinoma","volume":"19","author":"Nakajima","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2022.108628_b0095","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00262-017-2038-3","article-title":"Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer","volume":"66","author":"Wesolowski","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2147\/CMAR.S151026","article-title":"Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy","volume":"9","author":"Chen","year":"2017","journal-title":"Cancer Manage. Res."},{"key":"10.1016\/j.intimp.2022.108628_b0105","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.7150\/jca.31755","article-title":"Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancer","volume":"10","author":"Yu","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.intimp.2022.108628_b0110","doi-asserted-by":"crossref","first-page":"e54824","DOI":"10.1371\/journal.pone.0054824","article-title":"Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study","volume":"8","author":"Basso","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2022.108628_b0115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00262-016-1953-z","article-title":"Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients","volume":"66","author":"Jordan","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1309\/AJCPPIBH3I1VRWXQ","article-title":"Splenic lymphoid subsets with less well-recognized phenotypes mimic aberrant antigen expression","volume":"140","author":"Aggarwal","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2022.108628_b0125","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/eji.202048666","article-title":"Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer","volume":"50","author":"Tavukcuoglu","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0130","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108628_b0135","doi-asserted-by":"crossref","first-page":"104317","DOI":"10.1016\/j.cellimm.2021.104317","article-title":"Human splenic myeloid derived suppressor cells: phenotypic and clustering analysis","volume":"363","author":"Cole","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0145","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","article-title":"Arginase I\u2013producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes","volume":"69","author":"Rodriguez","year":"2009","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2022.108628_b0150","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00262-012-1294-5","article-title":"Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology","volume":"61","author":"Dumitru","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0155","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3892\/mmr.2015.4601","article-title":"Expression of arginase I and inducible nitric oxide synthase in the peripheral blood and lymph nodes of HIV-positive patients","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2022.108628_b0160","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","article-title":"Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species","volume":"172","author":"Kusmartsev","year":"2004","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.108628_b0165","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","volume":"60","author":"Gabitass","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"39","key":"10.1016\/j.intimp.2022.108628_b0170","doi-asserted-by":"crossref","first-page":"64505","DOI":"10.18632\/oncotarget.11352","article-title":"Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies","volume":"7","author":"Shou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2022.108628_b0175","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4049\/jimmunol.1202088","article-title":"Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8\/A9 proinflammatory proteins","volume":"190","author":"Wang","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin\u2013cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.coi.2007.06.004","article-title":"CD8 T cell dysfunction during chronic viral infection","volume":"19","author":"Shin","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0190","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2022.108628_b0195","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4049\/jimmunol.170.1.477","article-title":"Ablation of CD8 and CD4 T cell responses by high viral loads","volume":"170","author":"Fuller","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0200","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen\u2013specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2022.108628_b0205","doi-asserted-by":"crossref","first-page":"e30852","DOI":"10.1371\/journal.pone.0030852","article-title":"Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization","volume":"7","author":"Baitsch","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2022.108628_b0210","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2022.108628_b0215","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00262-015-1752-y","article-title":"Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression","volume":"64","author":"Japp","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0220","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2022.108628_b0225","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0092-8674(02)01139-X","article-title":"Molecular and functional profiling of memory CD8 T cell differentiation","volume":"111","author":"Kaech","year":"2002","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.intimp.2022.108628_b0230","doi-asserted-by":"crossref","first-page":"e26214","DOI":"10.1097\/MD.0000000000026214","article-title":"Peripheral blood CD45RO+T cells is a predictor of the effectiveness of neoadjuvant chemoradiotherapy in locally advanced rectal cancer","volume":"100","author":"Zhai","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.intimp.2022.108628_b0235","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/cam4.1988","article-title":"The clinical implication of CD45RA(+) na\u00efve T cells and CD45RO(+) memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction","volume":"8","author":"Hang","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.intimp.2022.108628_b0240","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0090-1229(90)90160-R","article-title":"Isolation, phenotyping, and functional analysis of lymphocytes from human liver","volume":"56","author":"Hata","year":"1990","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.intimp.2022.108628_b0245","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.4049\/jimmunol.156.12.4707","article-title":"NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1\/VLA-4 interaction","volume":"156","author":"Fogler","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0250","first-page":"279","article-title":"Increase in liver-associated natural killer activity by polyribonucleotides","volume":"6","author":"Twilley","year":"1987","journal-title":"Nat. Immun. Cell Growth Regul."},{"key":"10.1016\/j.intimp.2022.108628_b0255","doi-asserted-by":"crossref","first-page":"106655","DOI":"10.1016\/j.intimp.2020.106655","article-title":"Comparative phenotypes of peripheral blood and spleen cells from cancer patients","volume":"85","author":"Cole","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"19","key":"10.1016\/j.intimp.2022.108628_b0260","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.intimp.2022.108628_b0265","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108628_b0270","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00535-005-1724-7","article-title":"Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial","volume":"41","author":"Sakamoto","year":"2006","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.108628_b0275","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3892\/mco.2017.1161","article-title":"Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: a phase-I clinical trial","volume":"6","author":"Liang","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0280","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/07357907.2012.700987","article-title":"The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas","volume":"30","author":"Balmanoukian","year":"2012","journal-title":"Cancer Invest."},{"key":"10.1016\/j.intimp.2022.108628_b0285","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3904\/kjim.2019.358","article-title":"Association between absolute lymphocyte count and overall mortality in patients with surgically resected gastric cancer","volume":"36","author":"Park","year":"2021","journal-title":"Korean J. Int. Med."},{"key":"10.1016\/j.intimp.2022.108628_b0290","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1016\/j.vaccine.2013.10.053","article-title":"Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours","volume":"31","author":"Wumkes","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2022.108628_b0295","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0300","first-page":"3317","article-title":"Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset","volume":"47","author":"Berd","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2022.108628_b0305","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/path.2866","article-title":"In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival","volume":"224","author":"Ladoire","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.intimp.2022.108628_b0310","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/diagnostics11071298","article-title":"Decrease in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy as a predictive and prognostic marker in advanced ovarian cancer","volume":"11","author":"Sanna","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.intimp.2022.108628_b0315","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00280-021-04243-z","article-title":"Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis","volume":"87","author":"Liu","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2022.108628_b0320","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/bjc.2013.493","article-title":"The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer","volume":"109","author":"Mohammed","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2022.108628_b0325","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-07-4433","article-title":"HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma","volume":"14","author":"Han","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2022.108628_b0330","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-13-2830","article-title":"Prognostic and predictive values of the immunoscore in patients with rectal cancer","volume":"20","author":"Anitei","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2022.108628_b0335","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/MPA.0000000000000914","article-title":"Prognostic significance of tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemotherapy","volume":"46","author":"Nejati","year":"2017","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.intimp.2022.108628_b0340","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/00006676-200401000-00023","article-title":"CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma","volume":"28","author":"Fukunaga","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.intimp.2022.108628_b0345","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0350","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.108628_b0355","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0360","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial\u2020","volume":"24","author":"Reck","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0365","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2. Clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0370","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.intimp.2022.108628_b0375","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.intimp.2022.108628_b0380","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0385","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2001.19.5.1583","article-title":"Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy","volume":"19","author":"Balducci","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0390","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00262-008-0511-8","article-title":"Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus","volume":"57","author":"Westerterp","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0395","doi-asserted-by":"crossref","unstructured":"H. Peng, C.A. James, D.R. Cullinan, G.D. Hogg, J.L. Mudd, C. Zuo, R. Takchi, K.E. Caldwell, J. Liu, D.G. David, R.C. Fields, W.E. Gillanders, S.P. Goedegebuure, W.G. Hawkins, Neoadjuvant FOLFIRINOX therapy is associated with increased effector T cells and reduced suppressor cells in pancreatic cancer patients, Clin. Cancer Res. (2021) clincanres.0998.2021.","DOI":"10.1158\/1078-0432.CCR-21-0998"},{"key":"10.1016\/j.intimp.2022.108628_b0400","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","volume":"60","author":"Gabitass","year":"2011","journal-title":"Cancer Immunol. Immunother.: CII"},{"key":"10.1016\/j.intimp.2022.108628_b0405","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/oxfordjournals.jjco.a023173","article-title":"Serum Cytokine Level Fluctuations in Chemotherapy-induced Myelosuppression","volume":"26","author":"Chen","year":"1996","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0410","doi-asserted-by":"crossref","first-page":"39296","DOI":"10.1038\/srep39296","article-title":"PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment","volume":"6","author":"Iwata","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.108628_b0415","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1515\/CCLM.2007.025","article-title":"Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients","volume":"45","author":"Groblewska","year":"2007","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/j.intimp.2022.108628_b0420","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2478\/ams-2013-0023","article-title":"Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients","volume":"58","author":"\u0141awicki","year":"2013","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.intimp.2022.108628_b0425","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11523-018-0595-9","article-title":"Immunological correlates of response to immune checkpoint inhibitors in metastatic urothelial carcinoma","volume":"13","author":"Tzeng","year":"2018","journal-title":"Target. Oncol."},{"issue":"43","key":"10.1016\/j.intimp.2022.108628_b0430","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0435","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jtho.2020.09.027","article-title":"Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC","volume":"16","author":"Gaudreau","year":"2021","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.intimp.2022.108628_b0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-018-0368-0","article-title":"Effect of neoadjuvant chemotherapy on the immune microenvironment in non\u2013small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches","volume":"6","author":"Parra","year":"2018","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.intimp.2022.108628_b0445","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1038\/s41467-020-19933-0","article-title":"Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome","volume":"11","author":"Park","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.108628_b0450","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cellimm.2017.01.001","article-title":"Tumor antigen-specific CD8(+) T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer","volume":"313","author":"Lu","year":"2017","journal-title":"Cell Immunol."},{"key":"10.1016\/j.intimp.2022.108628_b0455","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2022.108628_b0460","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2022.108628_b0465","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2022.108628_b0470","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1128\/JVI.00639-09","article-title":"Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2022.108628_b0475","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2022.108628_b0480","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1172\/JCI127967","article-title":"Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes","volume":"129","author":"Gros","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2022.108628_b0485","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00262-017-2038-3","article-title":"3rd Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer","volume":"66","author":"Wesolowski","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108628_b0490","doi-asserted-by":"crossref","first-page":"1954761","DOI":"10.1080\/2162402X.2021.1954761","article-title":"Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry","volume":"10","author":"Park","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2022.108628_b0495","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000506075","article-title":"Prognostic significance of PD-1, PD-L1 and CD8 gene expression levels in gastric cancer","volume":"98","author":"Ito","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.intimp.2022.108628_b0500","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMoa051424","article-title":"Effector memory T cells, early metastasis, and survival in colorectal cancer","volume":"353","author":"Pag\u00e8s","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.108628_b0505","doi-asserted-by":"crossref","first-page":"e1424672","DOI":"10.1080\/2162402X.2018.1424672","article-title":"Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells","volume":"7","author":"Lieber","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2022.108628_b0510","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.108628_b0515","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The who's who of T-cell differentiation: human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108628_b0520","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10555-020-09947-x","article-title":"Role of myeloid-derived suppressor cells in metastasis","volume":"40","author":"Cole","year":"2021","journal-title":"Cancer Metastas. Rev."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:35:44Z","timestamp":1761586544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":104,"alternative-id":["S1567576922001126"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108628","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108628"}}